 |
|
Associations Between Intermediate Age-Related Macular Degeneration and Lutein and Zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS)
Ancillary Study of the Women's Health Initiative
Suzen M. Moeller, PhD;
Niyati Parekh, PhD;
Lesley Tinker, PhD;
Cheryl Ritenbaugh, PhD, MPH;
Barbara Blodi, MD;
Robert B. Wallace, MD;
Julie A. Mares, PhD; for the CAREDS Research Study Group
Arch Ophthalmol. 2006;124:1151-1162.
Objective To evaluate the relationship between dietary lutein plus zeaxanthin and intermediate age-related macular degeneration (AMD).
Design Women aged 50 to 79 years in Iowa, Wisconsin, and Oregon with intake of lutein plus zeaxanthin above the 78th (high) and below the 28th (low) percentiles at baseline in the Women's Health Initiative Observational Study were recruited 4 to 7 years later into the Carotenoids in Age-Related Eye Disease Study (CAREDS), when the presence of AMD was determined by fundus photographs. Logistic regression analyses examined the prevalence of AMD in 1787 CAREDS participants, after accounting for potential covariates.
Results The prevalence of intermediate AMD was not statistically different between the high and low lutein plus zeaxanthin intake recruitment groups after adjusting for age (odds ratio, 0.96; 95% confidence interval, 0.75-1.23). Limiting analyses to women younger than 75 years with stable intake of lutein plus zeaxanthin, without a history of chronic diseases that are often associated with diet changes, substantially lowered odds ratios (0.57; 95% confidence interval, 0.34-0.95). Exploratory analyses of advanced AMD in 34 participants resulted in protective, but statistically nonsignificant, associations in the overall sample and in women younger than 75 years.
Conclusion Diets rich in lutein plus zeaxanthin may protect against intermediate AMD in healthy women younger than 75 years.
Author Affiliations: Departments of Ophthalmology and Visual Sciences (Drs Moeller, Parekh, Blodi, and Mares) and Nutritional Sciences (Drs Moeller and Parekh), University of Wisconsin, Madison; Fred Hutchinson Cancer Research Center, Seattle, Wash (Dr Tinker); Department of Family and Community Medicine, University of Arizona, Tucson (Dr Ritenbaugh); and Department of Epidemiology, University of Iowa, Iowa City (Dr Wallace).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The rationale and evidence base for a protective role of macular pigment in age-related maculopathy
Loane et al.
Br. J. Ophthalmol. 2008;92:1163-1168.
ABSTRACT
| FULL TEXT
Xanthophylls are preferentially taken up compared with {beta}-carotene by retinal cells via a SRBI-dependent mechanism
During et al.
J. Lipid Res. 2008;49:1715-1724.
ABSTRACT
| FULL TEXT
Lutein and zeaxanthin for macular degeneration
Zhao and Sweet
Am J Health Syst Pharm 2008;65:1232-1238.
ABSTRACT
| FULL TEXT
Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin
Izumi-Nagai et al.
IOVS 2008;49:1679-1685.
ABSTRACT
| FULL TEXT
Associations Between Age-Related Nuclear Cataract and Lutein and Zeaxanthin in the Diet and Serum in the Carotenoids in the Age-Related Eye Disease Study (CAREDS), an Ancillary Study of the Women's Health Initiative
Moeller et al.
Arch Ophthalmol 2008;126:354-364.
ABSTRACT
| FULL TEXT
Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization
Izumi-Nagai et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2555-2562.
ABSTRACT
| FULL TEXT
The Prime Role of HDL to Transport Lutein into the Retina: Evidence from HDL-Deficient WHAM Chicks Having a Mutant ABCA1 Transporter
Connor et al.
IOVS 2007;48:4226-4231.
ABSTRACT
| FULL TEXT
The Relationship of Dietary Carotenoid and Vitamin A, E, and C Intake With Age-Related Macular Degeneration in a Case-Control Study: AREDS Report No. 22
Age-Related Eye Disease Study Research Group
Arch Ophthalmol 2007;125:1225-1232.
ABSTRACT
| FULL TEXT
|
